{"id":937639,"date":"2026-02-17T17:55:40","date_gmt":"2026-02-17T22:55:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/"},"modified":"2026-02-17T17:55:40","modified_gmt":"2026-02-17T22:55:40","slug":"uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/","title":{"rendered":"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC"},"content":{"rendered":"
\n

NEW YORK and NEW ORLEANS, Feb. 17, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti<\/a>, LLC (\u201cKSF\u201d) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026<\/u><\/strong> to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V.<\/a> (NasdaqGS: QURE) (\u201cuniQure\u201d or the \u201cCompany\u201d), if they purchased or otherwise acquired the Company\u2019s shares between September 24, 2025 and October 31, 2025, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Southern District of New York.<\/p>\n

What You May Do<\/p>\n

If you purchased shares of uniQure and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https:\/\/www.ksfcounsel.com\/cases\/nasdaqgs-qure\/<\/a> to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 13, 2026<\/u><\/strong>.<\/p>\n

About the Lawsuit<\/p>\n

uniQure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.<\/p>\n

During the Class Period, the Company represented to investors that there was a high likelihood that its leading drug candidate, AMT-130, would receive accelerated approval from the U.S. Food and Drug Administration (\u201cFDA\u201d) after the Company\u2019s planned Biologics License Application (\u201cBLA\u201d) submission in the first quarter of 2026. However, on November 3, 2025, the Company disclosed that \u201cthe FDA currently no longer agrees that the data from the Phase I\/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission\u201d and as a result, \u201cthe timing of the BLA submission for AMT-130 is now unclear.\u201d<\/p>\n

On this news, the price of uniQure\u2019s shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025.<\/p>\n

The case is Scocco v. uniQure N.V., et al., <\/em>Case No. 1:26-cv-01124.<\/p>\n

About Kahn Swick & Foti<\/a>, LLC<\/p>\n

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.<\/p>\n

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services<\/p>\n

To learn more about KSF, you may visit www.ksfcounsel.com<\/a>.<\/p>\n

Contact:<\/p>\n

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com<\/u>
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163<\/p>\n

CONNECT WITH US: Facebook<\/a> || Instagram<\/a> || YouTube<\/a> || TikTok<\/a> || LinkedIn<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK and NEW ORLEANS, Feb. 17, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (\u201cKSF\u201d) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (\u201cuniQure\u201d or the \u201cCompany\u201d), if they purchased or otherwise acquired the Company\u2019s shares between September 24, 2025 and October 31, 2025, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Southern District of New York. What You May Do If you purchased shares of uniQure and would like to discuss your legal rights and how this … <\/p>\n

Continue reading “uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937639","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nuniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and NEW ORLEANS, Feb. 17, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (\u201cKSF\u201d) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (\u201cuniQure\u201d or the \u201cCompany\u201d), if they purchased or otherwise acquired the Company\u2019s shares between September 24, 2025 and October 31, 2025, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Southern District of New York. What You May Do If you purchased shares of uniQure and would like to discuss your legal rights and how this … Continue reading "uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-17T22:55:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC\",\"datePublished\":\"2026-02-17T22:55:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/\"},\"wordCount\":554,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/\",\"name\":\"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE=\",\"datePublished\":\"2026-02-17T22:55:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/","og_locale":"en_US","og_type":"article","og_title":"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk","og_description":"NEW YORK and NEW ORLEANS, Feb. 17, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (\u201cKSF\u201d) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (\u201cuniQure\u201d or the \u201cCompany\u201d), if they purchased or otherwise acquired the Company\u2019s shares between September 24, 2025 and October 31, 2025, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Southern District of New York. What You May Do If you purchased shares of uniQure and would like to discuss your legal rights and how this … Continue reading \"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-17T22:55:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC","datePublished":"2026-02-17T22:55:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/"},"wordCount":554,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/","name":"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE=","datePublished":"2026-02-17T22:55:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjM2MyM3NDMwODczIzIwMTc2NzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937639"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937639\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}